Clik here to view.
Sales for Reva Medical up in Q3 following launch of bioresorbable scaffold
Shares in Reva Medical (ASX:RVA) rose today after the medical device maker posted its third-quarter financial results. The San Diego, Calif.-based company recorded a net loss of -$9 million on sales of...
View ArticleClik here to view.
OncoSec shares fall on preliminary data from skin cancer trial
Shares in OncoSec Medical (NSDQ:ONCS) fell nearly -60% this morning after the company revealed preliminary data from its Phase IIb trial of intratumoral delivery of Tavo in people with unresectable,...
View ArticleClik here to view.
Medtronic touts five-year data for In.Pact Admiral drug-coated balloon
Medtronic (NYSE:MDT) today touted five-year data for its In.Pact Admiral drug-coated balloon, highlighting the durability and efficacy of its device in people with peripheral artery disease in the...
View ArticleClik here to view.
Boston Scientific’s Eluvia drug-eluting stent succeeds in long lesions
Boston Scientific (NYSE:BSX) touted one-year data today from an analysis of its Eluvia drug-eluting vascular stent system, showing that the device is safe and effective in patients with long, complex,...
View ArticleClik here to view.
Surmodics reports positive one-year data for SurVeil drug-coated balloon
Surmodics (NSDQ:SRDX) touted data this week from an early feasibility study of the company’s SurVeil drug-coated balloon in patients with symptomatic peripheral artery disease due to de novo lesions of...
View ArticleClik here to view.
Insulet inks deal with Samsung to develop smartphone-controlled Omnipod
Insulet (NSDQ:PODD) said this week that it inked a deal with Samsung to develop an Omnipod insulin delivery system that would allow users to control their insulin pump therapy with a Galaxy smartphone....
View ArticleClik here to view.
Ocular Therapeutix shares fall after Q3 earnings miss
Shares in Ocular Therapeutix (NSDQ:OCUL) fell today after the company missed EPS estimates on Wall Street with its third-quarter financial results. The Bedford, Mass.-based company posted a net loss of...
View ArticleClik here to view.
FDA approves over-the-counter Primatene Mist inhaler
The FDA this week approved Amphastar Pharmaceuticals‘ (NSDQ:AMPH) over-the-counter Primatene Mist inhaler for the temporary relief of mild symptoms of intermittent asthma. The original version of...
View ArticleClik here to view.
InCarda Therapeutics raises $42m for inhaled atrial fibrillation drug
InCarda Therapeutics said today that it raised $42 million in an oversubscribed Series B financing round led by Sofinnova and HealthCap. Proceeds from the round are slated to support a Phase II trial...
View ArticleClik here to view.
Valeritas posts Street-beating Q3, sales up 37%
Shares in Valeritas (NSDQ:VLRX) rose today after the medical device maker topped expectations on Wall Street with its third-quarter financial results. The Bridgewater, N.J.-based company posted a net...
View ArticleClik here to view.
Philips launches below-the-knee PAD trial for drug-coated balloon
Philips (NYSE:PHG) said yesterday that it enrolled the first patient in a U.S. investigational device exemption trial for its Stellarex drug-coated balloon. The 354-patient Illumenate Below-the-Knee...
View ArticleClik here to view.
Enable Injections inks development deals for wearable drug-delivery device
Enable Injections said today that it inked development deals with Apellis Pharmaceuticals and UCB for its enFuse on-body drug-delivery device. The Cincinnati-based company has ongoing partnerships with...
View ArticleClik here to view.
Valeritas inks Middle East distro deal for V-Go insulin delivery device
Valeritas (NSDQ:VLRX) said today that it signed an exclusive distribution deal with Julphar for the commercialization of its V-Go wearable insulin delivery device in the member states of the Gulf...
View ArticleClik here to view.
Xeris Pharmaceuticals touts data for glucagon auto-injector
Xeris Pharmaceuticals (NSDQ:XERS) touted data this month for its ready-to-use glucagon auto-injector, highlighting the device’s efficacy and usability. The Chicago-based company’s rescue pen is under...
View ArticleClik here to view.
FDA warns on pain drugs for implantable pumps
The FDA today warned doctors and patients about the serious complications that can occur when using the wrong painkillers with implantable drug pumps. Dosing errors, pump failure, and infection are...
View ArticleClik here to view.
ivWatch inks distro deal for IV monitoring device
ivWatch said this week that it landed an international partner to manage the distribution of its continuous intravenous monitoring device. The Hampton, Va.-based company inked a deal with supplier New...
View ArticleClik here to view.
Lyndra touts positive results for long-acting drug-delivery tech
Lyndra Therapeutics reported positive results from a pharmacokinetics study of its once-weekly drug-delivery capsule, touting that it successfully transitioned a once-daily therapy to a weekly dosage...
View ArticleClik here to view.
Valeritas prices $36m public offering
Valeritas (NSDQ:VLRX) today priced an underwritten public offering of 75 million shares at 48¢ per share and accompanying warrants. The Bridgewater, N.J.-based company expects to reel in roughly $36...
View ArticleClik here to view.
Intersect ENT touts pooled analysis of steroid-releasing sinus implants
Intersect ENT (NSDQ:XENT) last week touted the publication of a pooled analysis of the company’s Propel Contour and Propel Mini steroid-eluting sinus implants. The company’s devices are designed to...
View ArticleClik here to view.
FDA extends decision date for Sage’s postpartum depression injection
Sage Therapeutics (NSDQ:SAGE) said today that the FDA extended its decision date for Sage’s Zulresso brexanolone injection to March 19, 2019. The U.S. regulatory agency was previously slated to decide...
View Article